Hypothalamic-Pituitary-Adrenal Axis Function in Chronic Fatigue Syndrome

  title={Hypothalamic-Pituitary-Adrenal Axis Function in Chronic Fatigue Syndrome},
  author={Filip Van Den Eede and Greta Moorkens and Boudewijn van Houdenhove and Paul Cosyns and Stephan Claes},
  pages={112 - 120}
There is evidence for a hypofunction of the hypothalamic-pituitary-adrenal (HPA) axis in a proportion of the patients with chronic fatigue syndrome (CFS), despite the negative studies and methodological difficulties. In this review, we focus on challenge studies and on the role of the HPA axis in the pathogenesis of CFS. Mild hypocortisolism, blunted adrenocorticotropin response to stressors and enhanced negative feedback sensitivity to glucocorticoids are the main findings. Several underlying… 

Figures and Tables from this paper

A Review of Hypothalamic-Pituitary-Adrenal Axis Function in Chronic Fatigue Syndrome

Given the interindividual variation in the effectiveness of existing biological and psychological treatments, the need for novel treatment strategies such as those which target the HPA axis is clear.

HPA-axis dysfunction in chronic fatigue syndrome: clinical implications.

TO THE EDITOR: There is evidence for a hypofunction of the hypothalamic-pituitary-adrenal (HPA) axis in a proportion of the patients with chronic fatigue syndrome (CFS). Mild hypocortisolism, blunted

Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome

CFS is globally associated with reduced cortisol responses in the combined low-dose dexamethasone/corticotropin-releasing factor test, but this effect is only clearly present in CFS patients without a history of ELS, which provides further support for an enhanced glucocorticoid negative feedback and/or a reduced central HPA axis drive in C FS.

Fibromyalgia and chronic fatigue: the underlying biology and related theoretical issues.

This chapter will focus on inflammatory and oxidative stress pathways and on the neuroendocrine system, which have been more commonly examined and suggest a role for the hypothalamic-pituitary-adrenal axis and cortisol in the pathogenesis of these syndromes.

Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways

Findings show that activation of immune-inflammatory and O&NS pathways in ME/CFS are probably not secondary to HPA axis hypoactivity and thatactivation of these pathways may underpin HPA Axis hypofunction in ME /CFS.

Model-Based Therapeutic Correction of Hypothalamic-Pituitary-Adrenal Axis Dysfunction

A model-based predictive control (MPC) methodology is used to estimate robust treatment courses for displacing the HPA axis from an abnormal hypocortisol steady state back to a healthy cortisol level.

Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation

Three hypothalamic mechanisms of fatigue in multiple sclerosis are discussed: general hypothalamic-pituitary-adrenal axis hyperactivity, disordered orexin neurotransmission, and potential mechanisms of weight dysregulation caused by hypothalamic dysfunction.

Chronic fatigue syndrome--a neuroimmunological model.




The HPA axis and the genesis of chronic fatigue syndrome

  • A. Cleare
  • Psychology
    Trends in Endocrinology & Metabolism
  • 2004

The low dose ACTH test in chronic fatigue syndrome and in health

Whether the 1 μg ACTH test would support such a dysregulation in CFS is established and the relative novelty of this test in clinical practice and the uncertainty with regard to appropriate cut‐off values for normality are compared.

Evidence for and Pathophysiologic Implications of Hypothalamic‐Pituitary‐Adrenal Axis Dysregulation in Fibromyalgia and Chronic Fatigue Syndrome

It is established that impaired activation of the hypothalamic‐pituitary‐adrenal (HPA) axis is an essential neuroendocrine feature of Chronic fatigue syndrome and this finding provides an important clue to the development of more effective treatment to this disabling condition.

The neuroendocrinology of chronic fatigue syndrome.

  • A. Cleare
  • Psychology, Medicine
    Endocrine reviews
  • 2003
It is suggested that more prospective cohort studies be undertaken in groups at high risk for CFS, that patients with CFS are followed up into recovery, and that multidimensional assessments are undertaken to unravel the influence of the various confounding factors on the observed endocrine changes in CFS.

Naloxone-mediated activation of the hypothalamic–pituitary–adrenal axis in chronic fatigue syndrome

The extent of opioid inhibition of HPA activity in CFS is investigated as a possible explanation for the reputed HPA hypofunctioning in patients with CFS and naloxone mediated activation of the HPA is attenuated.

Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome.

It is suggested that fibromyalgia is related to a neuroendocrine disorder characterized by hyperreactive pituitary ACTH release and a relative adrenal hyporesponsiveness, which might serve clinically as an explanation for the reduced aerobic capacity and impaired muscle performance these patients display.

Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.

Although it cannot definitively account for the etiology of the mild glucocorticoid deficiency seen in chronic fatigue syndrome patients, the enhanced adrenocortical sensitivity to exogenous ACTH and blunted ACTH responses to oCRH are incompatible with a primary adrenal insufficiency.

Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome

The small number of CFS patients investigated in earlier studies may have played a role in the interpretation of the results, and the data have not always been well characterized and were sometimes conflicting.